This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2020, the FDA halted Johnson & Johnson’s COVID-19 vaccine production at a contract manufacturing facility after discovering quality control issues. One notable success story is Moderna’s mRNA vaccine development for COVID-19, which benefited from early regulatory engagement and streamlined approval pathways.
Some diseases are caused by mutations in large genes that exceed the packaging limits of existing vectors like adeno-associated virus (AAV). AAV is a small virus that lacks a lipid membrane and carries a single-stranded piece of DNA stretching 4.7 Vectors also differ in the duration of their expression.
This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. mRNA Technology Transfer Programme Moves Into Phase 2.0, 2026–2030).
CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines for Children program Merck , operating as MSD outside the United States and Canada, has announced a key regulatory milestone for its respiratory syncytial virus (RSV) prevention program.
Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of Beyfortus® (nirsevimab) will begin in early Q3 2025.
By binding to the active site of the protease, the drug prevents this cleavage process, effectively halting viral assembly and impeding the virus’s ability to produce future virions. [1] “Second Generation Oral Mpro Inhibitor for COVID-19 Treatment Proceeds in Phase 3 Study” Precision Vaccinations.
Zenrelia comes with serious warnings, including a boxed warning against the use of Zenrelia during vaccination. CVM also objected to the truncation of other information about the timing of vaccines in these promotional materials. Zenrelia promotional materials also included claims about clinical data that the Agency found actionable.
He also has two current external positions as a member of the Scientific Advisory Board for Refeyn, a technology innovation university spin out, and as chair of Glen Clova Scientific, an early-stage vaccine development company.
Such models will, in turn, make it much easier to invent the sorts of platform tools that Amodei asserts “drive >50% of progress in biology,” such as CRISPR and mRNA vaccines, because the creation of these tools ultimately derive from a deeper understanding of how cells work.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., Kennedy Jr.
By Jonathan Gardner • Updated April 9, 2025 Latest in Marketing Soleno sales of new Prader-Willi drug rise faster than expected By Ben Fidler Lilly gets FDA OK of modified dosing for Alzheimer’s drug By Jonathan Gardner Medical groups, pregnant doctor sue RFK Jr.
While the two treatments are constructed differently, they both use the same kind of engineered virus to deliver a replacement gene to the body’s muscles. The man died of complications from acute liver failure in June.
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. However, Dyadic has now sharpened its strategic focus on commercializing non-therapeutic proteins—input molecules that are crucial for downstream manufacturing and production processes in various industries. “We
Temporary Recommendations: Strengthened Global Coordination and National Action The revised temporary recommendations, applicable until at least 20 August 2025, target all WHO Member States experiencing mpox virus (MPXV) transmission. Differentiating between virus clades and employing genomic sequencing to inform public health decisions.
Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.
A Life-Course Approach to Immunization: Prioritizing Vaccination at Every Age to Unlock the Full Potential of Lifelong Health In a striking demographic milestone, the global population is undergoing a historic transformation: for the first time ever, the number of adults over the age of 65 now exceeds that of children under the age of five.
MONDAY, May 6, 2024 -- Scientists are busy working on a vaccine that might fight strains of the COVID virus SARS-CoV-2 that haven't even emerged yet.The effort from a British team at the University of Cambridge is already showing promise in mouse.
10, 2023 (Healthday News) -- The first vaccine to prevent infection with the chikungunya virus was approved by the U.S. FRIDAY, Nov. Food and Drug Administration on Thursday. The single-dose shot, known as Ixchiq, is approved for adults who are at.
1, 2024 -- A next-generation nasal vaccine for COVID-19 appears to do what injectable vaccines can’t -- actually stop the spread of the virus from person to person.Hamsters that received the nasal vaccine didn’t pass the virus on to. THURSDAY, Aug.
Early animal studies show that a single vaccine could protect the recipient from different variants of the coronaviruses that cause COVID-19, the flu and the common cold.
TUESDAY, May 21, 2024 -- Powerful COVID vaccines could be setting people’s immune systems up to successfully fight off not just future COVID variants, but other types of coronaviruses as well, a new study shows.People repeatedly vaccinated for.
27, 2024 -- More Americans believe in the effectiveness of vaccines developed to protect newborns and seniors against respiratory syncytial virus (RSV).More adults (52%) think the RSV vaccine given to pregnant women. FRIDAY, Dec. More than half of U.S.
18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.With U.S. vaccination rates falling, "I. FRIDAY, Oct.
A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven't worked -- largely because HIV mutates rapidly and hides key parts of itself from the immune system.
FRIDAY, May 24, 2024 -- Development and uptake of the human papilloma virus (HPV) vaccine has been crucial in reducing rates of virus-linked cervical cancers in women. Now, the accumulated data suggests the vaccine is saving men from fatal cancers.
The group, made up of virologists, epidemiologists, public health professionals, and biosafety specialists, has been working for over three years to shed light on one of the most pressing questions in modern global health: how did SARS-CoV-2, the virus responsible for COVID-19, first infect humans?
4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.
Those with aging immune systems struggle to fight off novel viruses and respond weakly to vaccination. Researchers were able to revitalize the immune system in mice.
18, 2024 -- A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. vaccination rates falling, "I. FRIDAY, Oct.
TUESDAY, July 9, 2024 -- Expectant mothers who get vaccinated to protect their newborns against respiratory syncytial virus (RSV) are not putting themselves or their babies at risk, new research affirms. It found that getting the shot during late.
THURSDAY, June 29, 2023 -- Americans ages 60 and up can get their vaccine for respiratory syncytial virus (RSV) this fall, the U.S. Centers for Disease Control and Prevention announced Thursday. On Thursday, Dr. Rochelle Walensky, the outgoing CDC.
28, 2023 -- About half of older adults (52 percent) have heard of the new vaccines against respiratory syncytial virus (RSV), Arexvy and Abrysvo, according to the National Poll on Healthy Aging released online on Aug. MONDAY, Aug. The poll,
Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.
TUESDAY, July 9, 2024 -- Expectant mothers who get vaccinated to protect their newborns against respiratory syncytial virus (RSV) are not putting themselves or their babies at risk, new research affirms.It found that getting the shot during late.
TUESDAY, April 16, 2024 -- Genetics-based “one-and-done” vaccines for the flu and COVID could prove more effective and easier to craft than current jabs, researchers report.These new vaccines would target viruses using a different response to.
Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.
GSK expects its respiratory syncytial virusvaccine will be a multibillion dollar product. But at the beginning it’s predicting a slower launch than for its fast-selling shingles shot.
7, 2023 -- While it doesn't prevent infection altogether, new research shows the mpox vaccine does reduces the severity of disease in those who fall ill from the virus. THURSDAY, Sept. An international team of scientists found that those people who.
22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV). FRIDAY, Sept. Following approval one month ago by the U.S. Food and Drug Administration, the Centers for.
THURSDAY, April 17, 2025 A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV), meningitis and a mosquito-borne illness called chikungunya.The panel, k.
22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. TUESDAY, Aug. Food and Drug Administration approval of the shot, called Abrysvo, on.
22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. TUESDAY, Aug. Food and Drug Administration approval of the shot, called Abrysvo, on.
18, 2023 -- Most parents plan to have their kids vaccinated against influenza and respiratory syncytial virus (RSV), even as COVID-19 vaccine acceptance flags, a new poll finds.Seven in 10 parents (71%) plan to have their children get. MONDAY, Dec.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content